Rationales, evidence, and design considerations for fractionated radioimmunotherapy

Gerald L Denardo, Jeffery Schlom, Donald J. Buchsbaum, Ruby F. Meredith, Joseph A. O'Donoghue, George Sgouros, John L. Humm, Sally J. DeNardo

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Although fractionation can be used in a discrete radiobiologic sense, herein it is generally used in the broader context of administration of multiple, rather than single, doses of radionuclide for radioimmunotherapy (RIT) or other targeted radionuclide therapies. Fractionation is a strategy for overcoming heterogeneity of monoclonal antibody (MAb) distribution in the tumor and the consequent non-uniformity of tumor radiation doses. Additional advantages of fractionated RIT are the ability to 1) provide patient-specific radionuclide and radiation dosing, 2) control toxicity by titration of the individual patient, 3) reduce toxicity, 4) increase the maximum tolerated dose (MTD) for many patients, 5) increase tumor radiation dose and efficacy, and 6) prolong tumor response by permitting treatment over time. However, fractionated RIT has logistic and economic implications. Preclinical and clinical data substantiate the advantages of fractionated RIT, although the radiobiology for conventional external beam radiotherapy does not provide a straightforward rationale for RIT unless fractionation leads to more uniform distribution of radiation dose throughout the tumor. Preclinical data have shown that toxicity and mortality can be reduced while efficacy is increased, thereby providing inferential evidence of greater uniformity of radiation dose. Direct evidence of superior dosimetry and tumor activity distribution has also been found. Clinical data have shown that toxicity can be better controlled and reduced and the MTD extended for many patients. It is clear that fractionated RIT can only fulfill its potential if the effects of critical issues, such as the number and amount of radionuclide doses, the radionuclide physical and effective half-life, and the dose interval, are better characterized.

Original languageEnglish (US)
Pages (from-to)1332-1348
Number of pages17
JournalCancer
Volume94
Issue number4 SUPPL.
StatePublished - Feb 15 2002

Fingerprint

Radioimmunotherapy
Radioisotopes
Radiation
Neoplasms
Maximum Tolerated Dose
Radiobiology
Half-Life
Radiotherapy
Monoclonal Antibodies
Economics
Mortality
Therapeutics

Keywords

  • Antibody
  • Cancer
  • Fractionation
  • Radiation
  • Radioimmunotherapy
  • Radioisotope
  • Radionuclide
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Denardo, G. L., Schlom, J., Buchsbaum, D. J., Meredith, R. F., O'Donoghue, J. A., Sgouros, G., ... DeNardo, S. J. (2002). Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer, 94(4 SUPPL.), 1332-1348.

Rationales, evidence, and design considerations for fractionated radioimmunotherapy. / Denardo, Gerald L; Schlom, Jeffery; Buchsbaum, Donald J.; Meredith, Ruby F.; O'Donoghue, Joseph A.; Sgouros, George; Humm, John L.; DeNardo, Sally J.

In: Cancer, Vol. 94, No. 4 SUPPL., 15.02.2002, p. 1332-1348.

Research output: Contribution to journalArticle

Denardo, GL, Schlom, J, Buchsbaum, DJ, Meredith, RF, O'Donoghue, JA, Sgouros, G, Humm, JL & DeNardo, SJ 2002, 'Rationales, evidence, and design considerations for fractionated radioimmunotherapy', Cancer, vol. 94, no. 4 SUPPL., pp. 1332-1348.
Denardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 2002 Feb 15;94(4 SUPPL.):1332-1348.
Denardo, Gerald L ; Schlom, Jeffery ; Buchsbaum, Donald J. ; Meredith, Ruby F. ; O'Donoghue, Joseph A. ; Sgouros, George ; Humm, John L. ; DeNardo, Sally J. / Rationales, evidence, and design considerations for fractionated radioimmunotherapy. In: Cancer. 2002 ; Vol. 94, No. 4 SUPPL. pp. 1332-1348.
@article{e6cfca44b2d6422e82a79bf571f1e352,
title = "Rationales, evidence, and design considerations for fractionated radioimmunotherapy",
abstract = "Although fractionation can be used in a discrete radiobiologic sense, herein it is generally used in the broader context of administration of multiple, rather than single, doses of radionuclide for radioimmunotherapy (RIT) or other targeted radionuclide therapies. Fractionation is a strategy for overcoming heterogeneity of monoclonal antibody (MAb) distribution in the tumor and the consequent non-uniformity of tumor radiation doses. Additional advantages of fractionated RIT are the ability to 1) provide patient-specific radionuclide and radiation dosing, 2) control toxicity by titration of the individual patient, 3) reduce toxicity, 4) increase the maximum tolerated dose (MTD) for many patients, 5) increase tumor radiation dose and efficacy, and 6) prolong tumor response by permitting treatment over time. However, fractionated RIT has logistic and economic implications. Preclinical and clinical data substantiate the advantages of fractionated RIT, although the radiobiology for conventional external beam radiotherapy does not provide a straightforward rationale for RIT unless fractionation leads to more uniform distribution of radiation dose throughout the tumor. Preclinical data have shown that toxicity and mortality can be reduced while efficacy is increased, thereby providing inferential evidence of greater uniformity of radiation dose. Direct evidence of superior dosimetry and tumor activity distribution has also been found. Clinical data have shown that toxicity can be better controlled and reduced and the MTD extended for many patients. It is clear that fractionated RIT can only fulfill its potential if the effects of critical issues, such as the number and amount of radionuclide doses, the radionuclide physical and effective half-life, and the dose interval, are better characterized.",
keywords = "Antibody, Cancer, Fractionation, Radiation, Radioimmunotherapy, Radioisotope, Radionuclide, Therapy",
author = "Denardo, {Gerald L} and Jeffery Schlom and Buchsbaum, {Donald J.} and Meredith, {Ruby F.} and O'Donoghue, {Joseph A.} and George Sgouros and Humm, {John L.} and DeNardo, {Sally J.}",
year = "2002",
month = "2",
day = "15",
language = "English (US)",
volume = "94",
pages = "1332--1348",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Rationales, evidence, and design considerations for fractionated radioimmunotherapy

AU - Denardo, Gerald L

AU - Schlom, Jeffery

AU - Buchsbaum, Donald J.

AU - Meredith, Ruby F.

AU - O'Donoghue, Joseph A.

AU - Sgouros, George

AU - Humm, John L.

AU - DeNardo, Sally J.

PY - 2002/2/15

Y1 - 2002/2/15

N2 - Although fractionation can be used in a discrete radiobiologic sense, herein it is generally used in the broader context of administration of multiple, rather than single, doses of radionuclide for radioimmunotherapy (RIT) or other targeted radionuclide therapies. Fractionation is a strategy for overcoming heterogeneity of monoclonal antibody (MAb) distribution in the tumor and the consequent non-uniformity of tumor radiation doses. Additional advantages of fractionated RIT are the ability to 1) provide patient-specific radionuclide and radiation dosing, 2) control toxicity by titration of the individual patient, 3) reduce toxicity, 4) increase the maximum tolerated dose (MTD) for many patients, 5) increase tumor radiation dose and efficacy, and 6) prolong tumor response by permitting treatment over time. However, fractionated RIT has logistic and economic implications. Preclinical and clinical data substantiate the advantages of fractionated RIT, although the radiobiology for conventional external beam radiotherapy does not provide a straightforward rationale for RIT unless fractionation leads to more uniform distribution of radiation dose throughout the tumor. Preclinical data have shown that toxicity and mortality can be reduced while efficacy is increased, thereby providing inferential evidence of greater uniformity of radiation dose. Direct evidence of superior dosimetry and tumor activity distribution has also been found. Clinical data have shown that toxicity can be better controlled and reduced and the MTD extended for many patients. It is clear that fractionated RIT can only fulfill its potential if the effects of critical issues, such as the number and amount of radionuclide doses, the radionuclide physical and effective half-life, and the dose interval, are better characterized.

AB - Although fractionation can be used in a discrete radiobiologic sense, herein it is generally used in the broader context of administration of multiple, rather than single, doses of radionuclide for radioimmunotherapy (RIT) or other targeted radionuclide therapies. Fractionation is a strategy for overcoming heterogeneity of monoclonal antibody (MAb) distribution in the tumor and the consequent non-uniformity of tumor radiation doses. Additional advantages of fractionated RIT are the ability to 1) provide patient-specific radionuclide and radiation dosing, 2) control toxicity by titration of the individual patient, 3) reduce toxicity, 4) increase the maximum tolerated dose (MTD) for many patients, 5) increase tumor radiation dose and efficacy, and 6) prolong tumor response by permitting treatment over time. However, fractionated RIT has logistic and economic implications. Preclinical and clinical data substantiate the advantages of fractionated RIT, although the radiobiology for conventional external beam radiotherapy does not provide a straightforward rationale for RIT unless fractionation leads to more uniform distribution of radiation dose throughout the tumor. Preclinical data have shown that toxicity and mortality can be reduced while efficacy is increased, thereby providing inferential evidence of greater uniformity of radiation dose. Direct evidence of superior dosimetry and tumor activity distribution has also been found. Clinical data have shown that toxicity can be better controlled and reduced and the MTD extended for many patients. It is clear that fractionated RIT can only fulfill its potential if the effects of critical issues, such as the number and amount of radionuclide doses, the radionuclide physical and effective half-life, and the dose interval, are better characterized.

KW - Antibody

KW - Cancer

KW - Fractionation

KW - Radiation

KW - Radioimmunotherapy

KW - Radioisotope

KW - Radionuclide

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0037083345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037083345&partnerID=8YFLogxK

M3 - Article

C2 - 11877764

AN - SCOPUS:0037083345

VL - 94

SP - 1332

EP - 1348

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4 SUPPL.

ER -